Literature DB >> 24140000

Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.

E Xylinas1, B D Robinson2, L A Kluth3, B G Volkmer4, R Hautmann5, R Küfer6, M Zerbib7, E Kwon8, R H Thompson8, S A Boorjian8, S F Shariat9.   

Abstract

PURPOSE: Expression of T-cell co-regulatory proteins has been associated with worse outcomes in patients with UCB. We aimed to confirm these findings.
MATERIALS AND METHODS: The study comprised tissue microarrays from 302 consecutive UCB patients treated with RC and lymphadenectomy between 1988 and 2003, 117 matched lymph nodes, and 50 cases of adjacent normal urothelium controls, which were evaluated for B7-H1, B7-H3, and PD-1 protein expression by immunohistochemistry.
RESULTS: B7-H3 and PD-1 expression were increased in cancers compared to adjacent normal urothelium (58.6% vs 6% and 65% vs 0%, respectively; both p values < 0.001). Meanwhile, B7-H1 was expressed in 25% of cancers (n = 76). Expression of B7-H3, B7-H1, and PD-1 were highly correlated between the primary tumors and metastatic nodes, with concordance rates of 90%, 86%, and 78% for B7H3, B7H1 and PD-1, respectively. Expression was not associated with clinicopathologic features, disease recurrence, cancer-specific or overall mortality. However, for the subgroup of patients with organ-confined disease (n = 96), B7-H1 expression was associated with an increased risk of overall mortality (p = 0.02) on univariate and trended toward an association on multivariate analyses (p = 0.06).
CONCLUSIONS: B7-H1, B7-H3 and PD-1 are altered in a large proportion of UCB. B7-H1 and PD-1 expression are differentially upregulated in cancer versus normal urothelium. High correlation between expression in LN and expression in RC specimens was observed. While expression was not associated with clinicopathologic features or standard outcomes in all patients, B7-H1 expression predicted overall mortality after RC in the subset of patients with organ-confined UCB.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Immunohistochemistry; Outcomes; Prognosis; Survival; T-cell regulators

Mesh:

Substances:

Year:  2013        PMID: 24140000     DOI: 10.1016/j.ejso.2013.08.023

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  61 in total

Review 1.  Immunotherapies for bladder cancer: a new hope.

Authors:  Farhad Fakhrejahani; Yusuke Tomita; Agnes Maj-Hes; Jane B Trepel; Maria De Santis; Andrea B Apolo
Journal:  Curr Opin Urol       Date:  2015-11       Impact factor: 2.309

Review 2.  New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.

Authors:  Ali Ghasemzadeh; Trinity J Bivalacqua; Noah M Hahn; Charles G Drake
Journal:  Clin Cancer Res       Date:  2015-12-18       Impact factor: 12.531

3.  Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma.

Authors:  Bo Zhang; Wei Yu; Xueru Feng; Zheng Zhao; Yu Fan; Yisen Meng; Shuai Hu; Yun Cui; Qun He; Hong Zhang; Dong Li; Zhisong He; Liqun Zhou; Jie Jin; Wenke Han
Journal:  Med Oncol       Date:  2017-04-13       Impact factor: 3.064

Review 4.  Emerging immunotherapies for bladder cancer.

Authors:  Joseph W Kim; Yusuke Tomita; Jane Trepel; Andrea B Apolo
Journal:  Curr Opin Oncol       Date:  2015-05       Impact factor: 3.645

Review 5.  New and promising strategies in the management of bladder cancer.

Authors:  Andrea B Apolo; Nicholas J Vogelzang; Dan Theodorescu
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

Review 6.  Immune checkpoint inhibitors: a new frontier in bladder cancer.

Authors:  Max Kates; Nikolai A Sopko; Hotaka Matsui; Charles G Drake; Noah M Hahn; Trinity J Bivalacqua
Journal:  World J Urol       Date:  2015-10-20       Impact factor: 4.226

Review 7.  The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.

Authors:  Alexander Sankin; Deepa Narasimhulu; Peter John; Benjamin Gartrell; Mark Schoenberg; Xingxing Zang
Journal:  Urol Oncol       Date:  2017-05-08       Impact factor: 3.498

8.  High expression of B7-H3 and CD163 in cancer tissues indicates malignant clinicopathological status and poor prognosis of patients with urothelial cell carcinoma of the bladder.

Authors:  Zhili Xu; Ling Wang; Jianhua Tian; Hongwei Man; Pengfei Li; Baoen Shan
Journal:  Oncol Lett       Date:  2018-03-05       Impact factor: 2.967

Review 9.  Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.

Authors:  Robert T Jones; Kenneth M Felsenstein; Dan Theodorescu
Journal:  Urol Clin North Am       Date:  2015-10-31       Impact factor: 2.241

10.  Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.

Authors:  Elodie Picarda; Kim C Ohaegbulam; Xingxing Zang
Journal:  Clin Cancer Res       Date:  2016-05-20       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.